ARS Pharmaceuticals Inc (NASDAQ: SPRY)’s stock price has plunge by 1.36relation to previous closing price of 13.97. Nevertheless, the company has seen a -3.28% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-30 that ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with profitability expected by 2027.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
The price-to-earnings ratio for ARS Pharmaceuticals Inc (NASDAQ: SPRY) is above average at 184.62x, Company’s 36-month beta value is 0.84.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 56.04M, and currently, short sellers hold a 29.37% ratio of that floaft. The average trading volume of SPRY on May 02, 2025 was 1.66M shares.
SPRY’s Market Performance
SPRY stock saw an increase of -3.28% in the past week, with a monthly gain of 13.01% and a quarterly increase of -0.91%. The volatility ratio for the week is 4.55%, and the volatility levels for the last 30 days are 7.22% for ARS Pharmaceuticals Inc (SPRY). The simple moving average for the past 20 days is 1.32% for SPRY’s stock, with a 9.55% simple moving average for the past 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 12.43% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.50% of loss for the given period.
Volatility was left at 7.22%, however, over the last 30 days, the volatility rate increased by 4.55%, as shares surge +8.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.00% upper at present.
During the last 5 trading sessions, SPRY fell by -3.28%, which changed the moving average for the period of 200-days by +21.44% in comparison to the 20-day moving average, which settled at $13.98. In addition, ARS Pharmaceuticals Inc saw 34.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 50,002 shares at the price of $12.30 back on Apr 07 ’25. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc, valued at $615,075 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, proposed sale 50,002 shares at $12.30 during a trade that took place back on Apr 07 ’25, which means that Shawver Laura is holding shares at $615,051 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.99 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at 0.09. The total capital return value is set at -0.01. Equity return is now at value 3.28, with 2.74 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 322.57.
Currently, EBITDA for the company is -3.08 million with net debt to EBITDA at 16.63. When we switch over and look at the enterprise to sales, we see a ratio of 15.02. The receivables turnover for the company is 9.73for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.26.
Conclusion
In a nutshell, ARS Pharmaceuticals Inc (SPRY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
